The Bay State’s next commercial drugmaker targets Andre the Giant's disease; Newton's SnapApp to move to Boston, double headcount
If you are having trouble viewing this email, click here
| |
| March 22, 2016 - A LOOK AT THE DAY'S BUSINESS STORIES FROM MEDIA OUTLETS AROUND BOSTON |
| COMPANIES IN TODAY'S MORNING EDITION Boston Private Financial Chiasma Oracle Providence Equity Partners Barracuda Networks Inc. Bottomline Technologies Government Center MBTA State House News Service Huntington Avenue theater College of Fine Arts BU BU Theatre Startups & VC Boston Medical Center The Bozzuto Group Boston Redevelopment Authority Bentall Kennedy Leggat McCall Properties The Harrison Albany Sarepta Therapeutics Station Reopening Government Center Station Green Line Massachusetts Department of Red Line Thermo Fisher Affymetrix Massachusetts General Hospital National Institutes of Health TRENDS & TOPICS IN TODAY'S MORNING EDITION Executive Compensation Management Awards Biotech Pharmaceuticals Jobs Roundup Marijuana Construction Funding Lists | Boston Private cuts CEO's pay by half after rocky year In 2015, the company failed to meet profitability goals in the face of a client exodus and a decline in share price. Senior executives paid the price. The Bay State’s next commercial drugmaker targets Andre the Giant's disease The worldwide market is about $750 million, and the company plans to price its treatment “to be competitive” with existing drugs, which cost between $45,000 and $65,000 a year. Newton's SnapApp to move to Boston, double headcount SnapApp plans to move from a 5,000-square-foot space in Newton to a 20,000-square-foot headquarters at 222 Berkeley St. in Boston by May. Five things you need to know today, and taking a nap at work Good morning, Boston, it’s Tuesday, or as I like to call it, the second Monday of the week. Here are the five most important things you need to know to help start your busy business day. Read Morning Edition >>
First look: ‘Transformative’ 710-unit residential project planned in South End 36 Duchenne experts sign UCLA letter in support of approval of Sarepta’s drug Gov't Center MBTA station reopens after two years, $82M rehab Thermo Fisher fights back versus rival bid in $1.3B Affymetrix acquisition NIH breakdown: The Massachusetts researchers, and communities, with the most funding in 2015 The List: The Bay State's largest commercial property managers Read Morning Edition >> |
| |
| Contact Us
Contact Us For all inquiries regarding this offer or subscription to the Boston Business Journal, please email us at: boston@bizjournals.com Cancel Email Subscription
To unsubscribe from this email - click here If you need other assistance, please let us know or contact:
bizjournals customer service, bizjournals 120 W. Morehead St., Charlotte, North Carolina 28202. © 2016 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of bizjournals. |
